Cytomegalovirus clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla
open to eligible people ages 18 years and up
This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.
Orange, California
Our lead scientists for Cytomegalovirus research studies include Piyanuch Kongtim.
Last updated: